- Antenatal Testing
- Carrier Testing
- Sweat Tests
- CFTR-Related Metabolic Syndrome (CRMS)
- Newborn Screening
- Prenatal Screening
Cystic fibrosis (CF) diagnostics market size was valued at USD 7.13 billion in 2022, growing at a CAGR of 18% from 2023-29. Cystic fibrosis (CF) is a chronic, genetic disease that causes persistent lung infections and limits the ability to breathe over time. Several mutations in the gene is responsible for Cystic fibrosis that encodes cystic fibrosis transmembrane conductance regulator (CFTR) protein. Patients with CF have inherited two copies of the defective CF gene one copy from each parent. Both parents must have at least one copy of the defective gene. Currently, there are approximately 70,000 people who are suffering from cystic fibrosis worldwide, according to the Cystic Fibrosis Foundation (CFF). Some of the popular methods of diagnosis are antenatal testing, carrier testing, and other tests such as genetic tests and sweat tests According to Cystic Fibrosis Foundation, the incidence of these hereditary disorders is constantly growing. Nonprofit organizations are investing huge amounts of funds to find various therapeutics for CF and to support research & developmental activities.
In February 2018, Luminex's xTAG Cystic Fibrosis 71 Kit v2 was approved for sale with LICENSALE.COM in Brazil. In March 2017, Elucigene Diagnostics announced the official launch of a new CF-Italia kit (CF1ITB1). In April 2017, Elucigene Diagnostics partnered with Southern Cross Diagnostics in order to expand in Australia and New Zealand markets.
Study Period
Base Year
CAGR
Largest Market
Fastest Growing Market
The major driver for the market is improved diagnostic technologies. Increase in investment and awareness about genetic diseases are aiding in development of diagnostic technologies, which will fuel the market growth. The high cost of the drugs and treatment may hamper the growth of the market. The global cystic fibrosis diagnostics market is expected to witness tremendous growth. Novel diagnostic tools for cystic fibrosis are being developed. The scientists at Stanford University, have developed a DNA test for the accurate and comprehensive screening of newborns for cystic fibrosis. By this test the next-generation DNA sequencing can be identified and this test is considered to be less expensive and less time-consuming technology.
The cystic fibrosis (CF) diagnostics market size was valued at USD 7.13 billion in 2022.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.
The cystic fibrosis (CF) diagnostics market key players are: Elucigene, Asper Biogene, ELITechGroup, Natera, Inc., Randox Laboratories Ltd., Luminex Corporation, Appolon Bioteck, Arazy Group, Illumina Inc.